Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial.
Halton J, Brandão LR, Luciani M, Bomgaars L, Chalmers E, Mitchell LG, Nurmeev I, Sharathkumar A, Svirin P, Gorbatikov K, Tartakovsky I, Simetzberger M, Huang F, Sun Z, Kreuzer J, Gropper S, Reilly P, Brueckmann M, Albisetti M; DIVERSITY Trial Investigators. Halton J, et al. Among authors: bomgaars l. Lancet Haematol. 2021 Jan;8(1):e22-e33. doi: 10.1016/S2352-3026(20)30368-9. Epub 2020 Dec 5. Lancet Haematol. 2021. PMID: 33290737 Clinical Trial.
Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability.
Halton JML, Albisetti M, Biss B, Bomgaars L, Brueckmann M, Gropper S, Harper R, Huang F, Luciani M, Maas H, Tartakovsky I, Mitchell LG. Halton JML, et al. Among authors: bomgaars l. J Thromb Haemost. 2017 Nov;15(11):2147-2157. doi: 10.1111/jth.13847. Epub 2017 Oct 26. J Thromb Haemost. 2017. PMID: 28921890 Free article. Clinical Trial.
Design and rationale for the DIVERSITY study: An open-label, randomized study of dabigatran etexilate for pediatric venous thromboembolism.
Albisetti M, Biss B, Bomgaars L, Brandão LR, Brueckmann M, Chalmers E, Gropper S, Harper R, Huang F, Luciani M, Manastirski I, Mitchell LG, Tartakovsky I, Wang B, Halton JML. Albisetti M, et al. Among authors: bomgaars l. Res Pract Thromb Haemost. 2018 Mar 25;2(2):347-356. doi: 10.1002/rth2.12086. eCollection 2018 Apr. Res Pract Thromb Haemost. 2018. PMID: 30046738 Free PMC article.
Phase 3, single-arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design.
Luciani M, Albisetti M, Biss B, Bomgaars L, Brueckmann M, Chalmers E, Gropper S, Halton JML, Harper R, Huang F, Manastirski I, Mitchell LG, Tartakovsky I, Wang B, Brandão LR. Luciani M, et al. Among authors: bomgaars l. Res Pract Thromb Haemost. 2018 Apr 24;2(3):580-590. doi: 10.1002/rth2.12093. eCollection 2018 Jul. Res Pract Thromb Haemost. 2018. PMID: 30046763 Free PMC article.
Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children.
Brandão LR, Albisetti M, Halton J, Bomgaars L, Chalmers E, Mitchell LG, Nurmeev I, Svirin P, Kuhn T, Zapletal O, Tartakovsky I, Simetzberger M, Huang F, Sun Z, Kreuzer J, Gropper S, Brueckmann M, Luciani M; DIVERSITY Study Investigators. Brandão LR, et al. Among authors: bomgaars l. Blood. 2020 Feb 13;135(7):491-504. doi: 10.1182/blood.2019000998. Blood. 2020. PMID: 31805182 Free PMC article. Clinical Trial.
Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism.
Röshammar D, Huang F, Albisetti M, Bomgaars L, Chalmers E, Luciani M, Halton J, Mitchell LG, Bergstrand M, Ibrahim MMA, Joseph D, Tartakovsky I, Gropper S, Brueckmann M, Brandão LR. Röshammar D, et al. Among authors: bomgaars l. J Thromb Haemost. 2021 May;19(5):1259-1270. doi: 10.1111/jth.15277. Epub 2021 Mar 26. J Thromb Haemost. 2021. PMID: 33636042 Free PMC article.
Anticoagulant Effects of Dabigatran on Coagulation Laboratory Parameters in Pediatric Patients: Combined Data from Five Pediatric Clinical Trials.
Mitchell LG, Röshammar D, Huang F, Albisetti M, Brandão LR, Bomgaars L, Chalmers E, Halton J, Luciani M, Joseph D, Tartakovsky I, Gropper S, Brueckmann M. Mitchell LG, et al. Among authors: bomgaars l. Thromb Haemost. 2022 Sep;122(9):1573-1583. doi: 10.1055/s-0042-1744542. Epub 2022 Jul 31. Thromb Haemost. 2022. PMID: 35909257 Free PMC article.
Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia.
Brandão LR, Tartakovsky I, Albisetti M, Halton J, Bomgaars L, Chalmers E, Luciani M, Saracco P, Felgenhauer J, Lvova O, Simetzberger M, Sun Z, Mitchell LG. Brandão LR, et al. Among authors: bomgaars l. Blood Adv. 2022 Nov 22;6(22):5908-5923. doi: 10.1182/bloodadvances.2021005681. Blood Adv. 2022. PMID: 36150047 Free PMC article. Clinical Trial.
Dabigatran for Treatment and Secondary Prevention of Venous Thromboembolism in Pediatric Congenital Heart Disease.
Albisetti M, Tartakovsky I, Halton J, Bomgaars L, Chalmers E, Mitchell LG, Luciani M, Nurmeev I, Gorbatikov K, Miede C, Brueckmann M, Brandão LR; Study Investigators. Albisetti M, et al. Among authors: bomgaars l. J Am Heart Assoc. 2024 Feb 20;13(4):e028957. doi: 10.1161/JAHA.122.028957. Epub 2024 Feb 13. J Am Heart Assoc. 2024. PMID: 38348778 Free PMC article.
Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia.
Thompson PA, Murry DJ, Rosner GL, Lunagomez S, Blaney SM, Berg SL, Camitta BM, Dreyer ZE, Bomgaars LR. Thompson PA, et al. Among authors: bomgaars lr. Cancer Chemother Pharmacol. 2007 May;59(6):847-53. doi: 10.1007/s00280-006-0388-1. Epub 2006 Nov 29. Cancer Chemother Pharmacol. 2007. PMID: 17136402 Clinical Trial.
56 results